Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

agerafenib (RXDX-105)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Roche

Drug class:

BRAF inhibitor, RET inhibitor, CS-1 inhibitor

Related drugs:

›

KIF5B-RET fusion	Non Small Cell Lung Cancer	KIF5B-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
CCDC6-RET fusion	Colorectal Cancer	CCDC6-RET fusion	Colorectal Cancer	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3	RXDX-105 Sensitive: C3 – Early Trials RXDX-105 Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
NCOA4-RET fusion	Non Small Cell Lung Cancer	NCOA4-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D
EML4-RET fusion	Non Small Cell Lung Cancer	EML4-RET fusion	Non Small Cell Lung Cancer	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D	RXDX-105 Sensitive: D – Preclinical RXDX-105 Sensitive : D